BB Biotech AG
BB Biotech AG Fundamental Analysis
BB Biotech AG (BBAGF) shows moderate financial fundamentals with a PE ratio of -9.55, profit margin of 10.64%, and ROE of -13.91%. The company generates $-0.0B in annual revenue with weak year-over-year growth of 1.56%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 54.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BBAGF's fundamental strength across five key dimensions:
Efficiency Score
WeakBBAGF struggles to generate sufficient returns from assets.
Valuation Score
ModerateBBAGF shows balanced valuation metrics.
Growth Score
WeakBBAGF faces weak or negative growth trends.
Financial Health Score
ExcellentBBAGF maintains a strong and stable balance sheet.
Profitability Score
WeakBBAGF struggles to sustain strong margins.
Key Financial Metrics
Is BBAGF Expensive or Cheap?
P/E Ratio
BBAGF trades at -9.55 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BBAGF's PEG of 4.03 indicates potential overvaluation.
Price to Book
The market values BB Biotech AG at 1.46 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -37.66 times EBITDA. This is generally considered low.
How Well Does BBAGF Make Money?
Net Profit Margin
For every $100 in sales, BB Biotech AG keeps $10.64 as profit after all expenses.
Operating Margin
Core operations generate 1.72 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-13.91 in profit for every $100 of shareholder equity.
ROA
BB Biotech AG generates $-15.26 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BB Biotech AG generates limited operating cash flow of $542.44M, signaling weaker underlying cash strength.
Free Cash Flow
BB Biotech AG generates weak or negative free cash flow of $542.44M, restricting financial flexibility.
FCF Per Share
Each share generates $7.06 in free cash annually.
FCF Yield
BBAGF converts 10.25% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-9.55
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
4.03
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.46
vs 25 benchmark
P/S Ratio
Price to sales ratio
-142.54
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
758.29
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.14
vs 25 benchmark
ROA
Return on assets percentage
-0.15
vs 25 benchmark
ROCE
Return on capital employed
-0.02
vs 25 benchmark
How BBAGF Stacks Against Its Sector Peers
| Metric | BBAGF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -9.55 | 18.80 | Better (Cheaper) |
| ROE | -13.91% | 817.00% | Weak |
| Net Margin | 1063.86% | -55.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 1.03 | Strong (Low Leverage) |
| Current Ratio | 758.29 | 661.52 | Strong Liquidity |
| ROA | -15.26% | -23757.00% (disorted) | Weak |
BBAGF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BB Biotech AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-83.59%
Industry Style: Value, Dividend, Cyclical
DecliningEPS CAGR
-88.71%
Industry Style: Value, Dividend, Cyclical
DecliningFCF CAGR
42.67%
Industry Style: Value, Dividend, Cyclical
High Growth